MDT · Healthcare

Medtronic plc

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: everything published this earnings window

News · 2026-11-07

• Renal Denervation EvidenceImportance 31 · Surprise 42
  The article cites positive study results for Medtronic’s Symplicity Spyral renal denervation system and wider FDA labeling. It suggests these developments could support future procedure volumes and cash inflows from…

News · 2026-11-06

• Revenue Performance and MixImportance 47 · Surprise 22
  A third-party report said Medtronic revenue increased 13.7% year over year, exceeding analyst expectations. The report did not identify the reporting period or provide revenue by segment or geography. It also did not…
• Regulatory Approval MilestonesImportance 47 · Surprise 60
  The FDA expanded the labeling for Medtronic's Symplicity Spyral renal denervation system, broadening its use in hypertension and adding clinical data for patients with isolated systolic hypertension, chronic kidney…
• Renal Denervation EvidenceImportance 34 · Surprise 42
  Medtronic's Symplicity Spyral system met the primary endpoint in the SPYRAL AFFIRM post-approval study, with statistically significant blood-pressure reductions at six months across office, home, and 24-hour…
• Products and TechnologyImportance 31 · Surprise 42
  Medtronic showcased more than 120 products and solutions at the ninth China International Import Expo, its largest exhibition to date. Seven products debuted, many incorporating AI algorithms, and the company said…
• Strategic InitiativesImportance 31 · Surprise 42
  Medtronic participated in the ninth China International Import Expo, presenting more than 120 products and solutions, its largest CIIE exhibition to date. The company unveiled seven products in China and is preparing a…

News · 2026-11-05

• Quarterly Earnings PerformanceImportance 35 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion, up 13.7% year over year. Adjusted earnings were $1.45 per share, and the company beat estimates.
• Evolut TAVR Clinical PositioningImportance 33 · Surprise 24
  At the TCT annual conference, Medtronic presented the design and baseline characteristics of the Evolut EXPAND TAVR II trial. The global randomized study is evaluating the Evolut TAVR platform in patients aged 65 or…

News · 2026-11-04

• Quarterly Dividend DeclarationImportance 10 · Surprise 6
  Medtronic announced a quarterly dividend of $0.72 per share. The dividend was also referenced in a separate November 4 report about the company’s recent quarterly earnings. The reports do not state the dividend’s…

News · 2026-11-03

• Renal Denervation EvidenceImportance 31 · Surprise 42
  Medtronic reported statistically significant and clinically meaningful blood pressure reductions at six months in the SPYRAL AFFIRM post-approval study of its Symplicity Spyral renal denervation system. The results…
• Quarterly Earnings PerformanceImportance 29 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion, up 13.7% year over year. Adjusted earnings were $1.45 per share, exceeding analyst expectations. The report also said Medtronic maintained a quarterly dividend of…

News · 2026-11-01

• Cardiac Ablation Clinical EvidenceImportance 17 · Surprise 24
  Medtronic reported positive real-world outcomes for its Affera Mapping and Ablation System among patients with atrial fibrillation and ventricular tachycardia. The company also highlighted favorable real-world data for…
• Competition and Market PositionImportance 10 · Surprise 6
  A report on Intuitive Surgical’s da Vinci business identified Medtronic and Johnson & Johnson as increasing competitors in robotic surgery. It noted that Intuitive’s recurring revenue from instruments, accessories, and…

News · 2026-10-30

• Product Liability LawsuitImportance 34 · Surprise 42
  Third-party reporting says plaintiffs Linda Dorn and Brooke Vasquez sued Medtronic over alleged defects in its 600 Series insulin pumps, claiming a defective retainer ring could cause severe hypoglycemia or…

News · 2026-10-22

• Revenue Performance and MixImportance 35 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion, representing a 13.7% year-over-year increase. Quarterly EPS was $1.45, indicating stronger-than-expected earnings performance alongside the revenue growth. The…
• Sphere-9 Ventricular Ablation ExpansionImportance 14 · Surprise 24
  Medtronic reported positive real-world registry results for its Affera Mapping and Ablation System with the Sphere-9 Catheter and PulseSelect Pulsed Field Ablation System at APHRS 2026. The APEX analysis included 1,050…

News · 2026-10-21

• Diabetes Business SeparationImportance 47 · Surprise 42
  Medtronic was reported to be completing the separation of MiniMed. The transaction is restructuring the company’s revenue mix by separating the diabetes business from the remaining medical-device portfolio. The…
• Product Launch and TransitionImportance 41 · Surprise 42
  Medtronic received European CE mark approval for the Vitalis portfolio of five next-generation pacemakers. The devices target conduction system pacing therapy and include remote-monitoring features. SKU…
• Octopus 4 Product RecallImportance 38 · Surprise 60
  The FDA issued a Class II recall covering 3,746 Medtronic biopsy kits. Material deviations affecting optical tracking triggered the recall and affect the company’s medical-surgical portfolio. The reported recall…
• Product Recall and SafetyImportance 38 · Surprise 60
  The U.S. Food and Drug Administration issued a Class II recall for 3,746 Medtronic biopsy kits. The recall concerns material deviations affecting optical tracking and involves the company’s medical-surgical portfolio.…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  Medtronic received European CE mark approval for its Vitalis portfolio of five next-generation pacemakers. The devices are designed for conduction system pacing therapy and include remote-monitoring features. The…
• Medical Devices Market GrowthImportance 37 · Surprise 56
  A ResearchAndMarkets report projects the global medical devices market will increase from $580.79 billion in 2026 to $817.78 billion by 2031. The forecast implies a 7.1% compound annual growth rate, supported by…
• Management ChangesImportance 22 · Surprise 42
  Medtronic’s board appointed Michael Marinaro as President. His expanded responsibilities include oversight of Greater China in addition to Medical Surgical and global commercial operations. The appointment changes…

News · 2026-10-20

• Quarterly Earnings PerformanceImportance 47 · Surprise 22
  Medtronic reported fiscal first-quarter 2027 revenue of $9.76 billion, up 13.7% year over year. Adjusted earnings per share was $1.45 for the quarter. The company scheduled its next earnings report for November 17,…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  Medtronic received a European CE mark for its Vitalis portfolio of five next-generation cardiac pacemakers, enabling sales across Europe. The devices use conduction system pacing to stimulate the heart’s natural…
• Cardiac Monitoring Market GrowthImportance 30 · Surprise 40
  The U.S. wireless cardiac monitoring systems market was valued at approximately $2.4 billion in 2025 and is projected to reach $5.2 billion by 2033, representing a 10.1% CAGR from 2026 to 2033. Growth is expected to be…

8-K · 2026-10-19

• MiniMed SeparationImportance 61 · Surprise 60
  Medtronic completed the separation of MiniMed Group, Inc. on October 15, 2026, creating MiniMed as an independent publicly traded company under the Nasdaq ticker MMED. Medtronic exchanged all of its remaining…

News · 2026-10-19

• Management ChangesImportance 34 · Surprise 42
  Medtronic appointed Michael Marinaro as president effective October 14, 2026. He will retain his existing responsibilities and add oversight of the company’s Greater China operations. His compensation package includes…

News · 2026-10-17

• Quarterly Earnings PerformanceImportance 33 · Surprise 6
  Medtronic reported quarterly revenue of $9.76 billion, exceeding analysts’ expectations. Quarterly EPS was $1.45, also above expectations. The digest does not provide year-over-year or sequential revenue changes,…
• Products and TechnologyImportance 17 · Surprise 24
  Medtronic’s Stealth AXiS surgical system and Corsano wearable were named to TIME’s Best Inventions of 2026. Stealth AXiS is an advanced surgical platform, while the Corsano device provides continuous cardiac…

News · 2026-10-16

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic completed the separation of MiniMed through an oversubscribed share exchange, ending Medtronic’s ownership stake in the diabetes technology business. Medtronic shareholders exchanged 55 million Medtronic…
• Products and TechnologyImportance 25 · Surprise 30
  Medtronic is expanding in cardiac ablation, robotics and structural heart, identifying these areas as high-growth markets. Hypertension therapy is receiving support from improved reimbursement, clinical evidence,…

News · 2026-10-15

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic completed the separation of MiniMed Group, Inc. on October 15, 2026, making MiniMed an independent Nasdaq-listed company. The transaction included an exchange offer for Medtronic’s remaining MiniMed shares…
• Licensing / Collaboration DealsImportance 30 · Surprise 42
  Medtronic joined the EU-funded EXIT-CVD research consortium with Philips, GE HealthCare and other healthcare companies. The consortium is focused on earlier detection, monitoring and treatment of cardiovascular…
• EU EXIT-CVD Research ConsortiumImportance 30 · Surprise 42
  Medtronic joined the European Union-funded EXIT-CVD research consortium with Philips, GE HealthCare and other healthcare companies on October 15, 2026. The consortium is co-funded by the EU Innovative Health Initiative…
• Products and TechnologyImportance 17 · Surprise 24
  Medtronic’s Stealth AXiS™ surgical system and Corsano™ multi-parameter wearable were named to TIME’s Best Inventions of 2026 list. The recognition highlights Medtronic’s connected-technology portfolio in surgical…

News · 2026-10-14

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic completed its exchange offer on October 9, 2026, exchanging all remaining 252,813,348 MiniMed common shares for 55,032,401 newly issued Medtronic ordinary shares. The offer was oversubscribed, with…

News · 2026-10-13

• MiniMed SeparationImportance 47 · Surprise 60
  Medtronic’s exchange offer for MiniMed Group common stock was oversubscribed, with investors tendering 298 million Medtronic ordinary shares. Medtronic plans to accept 55 million shares, implying a preliminary…
• mHealth Solutions Market GrowthImportance 35 · Surprise 48
  The global mHealth solutions market is projected to increase from $109.05 billion in 2026 to $275.44 billion by 2031, representing a 20.4% CAGR. Market expansion is supported by adoption of connected medical devices,…
• Bioelectronic Medicine Market GrowthImportance 30 · Surprise 40
  The global bioelectronic medicine device market is projected to grow from $2.13 billion in 2025 to $2.49 billion in 2026, a 16.7% CAGR. Growth is driven by healthcare-provider adoption of advanced neuromodulation…

News · 2026-10-12

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic’s exchange offer for MiniMed Group expired at midnight on October 9, 2026, and was oversubscribed. Medtronic will exchange all of its remaining 252,813,348 MiniMed shares at a ratio of 4.5939 MiniMed shares…
• Reimbursement and Payer MixImportance 40 · Surprise 42
  Medtronic achieved 96% U.S. reimbursement coverage for its VenaSeal system, reducing a stated adoption barrier for the vein-treatment product. New CPT codes were issued for the Altaviva and Symplicity Spyral systems,…
• Regulatory Approval MilestonesImportance 38 · Surprise 42
  Medtronic achieved 96% U.S. reimbursement coverage for the VenaSeal system, reducing a stated adoption barrier for the vein-treatment platform. The company also received new CPT codes for the Altaviva and Symplicity…
• Competition and Market PositionImportance 31 · Surprise 42
  Stryker is entering soft-tissue surgical robotics through a $400 million investment in CMR Surgical. The arrangement makes Stryker the exclusive U.S. distributor of CMR’s Versius robotic system, positioning it against…
• Urology Devices Market GrowthImportance 18 · Surprise 14
  The global urology devices market is projected to exceed $56 billion by 2030, implying a 7% compound annual growth rate. Growth is expected to be driven by the rising prevalence of urological disorders and increasing…

News · 2026-10-11

• MiniMed SeparationImportance 40 · Surprise 42
  Medtronic retained approximately 90% of MiniMed Group after MiniMed’s March initial public offering. Medtronic subsequently launched an exchange offer to complete the separation of MiniMed. The transaction changes…

News · 2026-10-09

• Revenue Performance and MixImportance 49 · Surprise 22
  Medtronic reported fiscal first-quarter revenue of USD 9.76 billion. Revenue increased 13.70 percent year over year. The reported quarter was Medtronic’s fiscal first quarter.
• MiniMed SeparationImportance 31 · Surprise 42
  Medtronic’s MiniMed share exchange offer is highlighted as a strategic separation initiative. The offer covers a significant number of shares and expires on October 9, 2026. The report does not disclose the number of…

News · 2026-10-08

• MiniMed SeparationImportance 61 · Surprise 60
  Medtronic set a final exchange ratio of 4.5939 MiniMed shares for each Medtronic ordinary share in its MiniMed Group split-off. The offer covers up to 225,361,295 newly issued MiniMed shares, representing approximately…
• Revenue Performance and MixImportance 38 · Surprise 6
  Medtronic’s fiscal first-quarter revenue increased to $9.76 billion. The reported quarterly revenue exceeded analyst expectations, indicating performance above consensus estimates. The digest does not provide…
• Quarterly Dividend DeclarationImportance 13 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend declaration was reported alongside quarterly revenue of $9.76 billion and adjusted earnings of $1.45 per share. The digest does not state the…

News · 2026-10-07

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic launched an exchange offer to separate its MiniMed diabetes unit from the company. The offer provides for up to 225,361,295 MiniMed common shares to be exchanged for Medtronic ordinary shares. Medtronic set a…
• Cardiac Ablation ExpansionImportance 59 · Surprise 82
  Medtronic appointed Felicia Kurz as vice president and general manager of its cardiac ablation solutions business. Revenue in the electrophysiology therapies division increased 88%, exceeding the materiality threshold…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  The FDA granted 510(k) clearance for Medtronic’s ApexCut™ EM navigated blades for sinus surgery in the United States. The clearance expands the company’s powered ENT instrument portfolio by integrating instrumentation…
• Revenue Performance and MixImportance 36 · Surprise 40
  Medtronic reported a 13.70% year-over-year revenue increase in the first quarter of fiscal 2027. The reported growth exceeded the company’s guidance for the quarter. The digest does not provide quarterly revenue…

News · 2026-10-06

• Guidance / OutlookImportance 63 · Surprise 76
  Third-party reporting said Medtronic raised its guidance for organic revenue growth and adjusted earnings per share after fiscal 2027 first-quarter revenue exceeded expectations. The report cited fiscal 2027…
• Revenue Performance and MixImportance 60 · Surprise 40
  Medtronic’s fiscal 2027 first-quarter revenue increased 13.70% year over year to $9.76 billion. The result exceeded expectations and supported an increase to the company’s organic revenue-growth guidance. The report…
• Research and Development ExpenseImportance 44 · Surprise 24
  Medtronic reported $2.9 billion of R&D investment in fiscal 2026. The investment supports innovation across medical devices and growth areas including pulsed field ablation, surgical robotics, renal denervation, and…
• Hypertension Therapy Clinical ProgressImportance 31 · Surprise 42
  Orchestra BioMed completed and exceeded enrollment in the pivotal BACKBEAT Global Pivotal Trial for its pacemaker-based hypertension therapy in collaboration with Medtronic. The trial randomized 330 patients and…
• Regulatory Approval MilestonesImportance 31 · Surprise 42
  Two Medtronic devices received permanent Category I CPT codes, strengthening their reimbursement pathways. The codes were cited in connection with Medtronic’s reported fiscal 2027 first-quarter performance and raised…